AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug
AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.
Read More
AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug
AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.
Read More
Chatha Foods makes a bumper debut, lists at 30% premium on BSE SME
The price band for the offer, purely a fresh issue, was fixed at Rs 52-56 a share
Read More
Wockhardt stock locked in 5% upper circuit after Prashant Jain, Madhusudan Kela and others invest in QIP
Other prominent names like ICICI Prudential, Mirae Asset Management, Tata Indian Opportunities Fund, Invesco India Smallcap Fund, Gagandeep Credit Capital and Subhkam Ventures were also issued shares in Wockhardt#39;s QIP.
Read More
Neelesh Surana’s wealth formula: Buy when near term is impaired and long term intact
In a rare media interaction, Mirae Asset’s maverick CIO talks about his investment strategy
Read More
It’s high time limits on overseas investment is increased
Restricting inflows into overseas ETFs is not in the best interest of investors.
Read More